Healthcare / Diagnostics & ResearchTSXV
$0.06
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-29816.00 · quality 31.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
2.8x
↓EV/EBITDA
9.7x
↓ROE
18.2%
↑Gross Margin
18.0%
↓Debt/Equity
1.41
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+38.2%
FCF CAGR
—
FCF margin
3.7%
FCF / Net income
0.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $17.7M · net income $1.2M · FCF $656193.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $17.7M | $17.7M | $12.6M | $9.2M | $6.7M |
| Net Income | $1.2M | $1.2M | $-2.2M | $185011.00 | $-2.2M |
| EBITDA | $1.5M | $1.5M | $-1.4M | $549428.00 | $-2.2M |
| EPS | 0.01 | 0.01 | -0.02 | 0.00 | -0.05 |
| Gross Margin | 18.0% | 18.0% | 18.7% | 17.1% | 20.1% |
| Operating Margin | -0.2% | -0.2% | -6.2% | -8.7% | -32.7% |
| Net Margin | 6.5% | 6.5% | -17.5% | 2.0% | -33.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.41 | 1.41 | 1.97 | 0.70 | 0.01 |
| Current Ratio | 0.56 | 0.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $656193.00 | $656193.00 | $-1.1M | $-29816.00 | $-1.8M |
| Returns | |||||
| ROE | 18.2% | 18.2% | -44.7% | 3.0% | -112.7% |
| Valuation | |||||
| P/E | 2.75 | 2.75 | — | 35.00 | — |
| EV/EBITDA | 9.67 | 9.67 | — | 17.81 | — |
| P/B | 0.95 | 0.95 | 1.86 | 0.90 | 3.26 |
| Growth & Yield | |||||
| Revenue Growth | 40.9% | 40.9% | 36.4% | 37.3% | — |
| EPS Growth | 150.0% | 150.0% | -1300.0% | 104.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-25.9%
EPS terminal req.
$0.00
Spread vs growth
175.9%
5Y implied EPS CAGR
-13.2%
EPS terminal req.
$0.01
Spread vs growth
163.2%
10Y implied EPS CAGR
-2.3%
EPS terminal req.
$0.01
Spread vs growth
152.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → 0.01
Residual
+10.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.